Healthcare Providers and Services
Company Overview of ARUP Laboratories, Inc.
ARUP Laboratories, Inc. operates a clinical and anatomic pathology reference laboratory in the United States. It offers ATOP, a laboratory analytics service to identify over-, under-, and mis-utilization of individual laboratory tests; ARUP Connect, an online information system for referral test management that enables to access test results, submit statistical data, and retrieve files; and ARUP Consult, a guide on PDA and Web platforms to assist the clinician with laboratory test selection and interpretation. The company also provides ARUP Direct, a start-to-finish outreach program to help clients; ARUP Gateway, an integrated customer test menu tool to serve the client's outreach medical co...
500 Chipeta Way
Salt Lake City, UT 84108-1221
Founded in 1984
Key Executives for ARUP Laboratories, Inc.
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President of Corporate Communications
Senior Technical Vice President
Administrative Vice President and Medical Director of Animal Reference Pathology Laboratory
Senior Vice President and Director of Marketing
Compensation as of Fiscal Year 2013.
ARUP Laboratories, Inc. Key Developments
ARUP Laboratories, Inc. Appoints Jerry W. Hussong as Chief Medical Officer and Director of Laboratories Replaces Sherrie Perkins
Jul 11 13
ARUP Laboratories, Inc. announced the appointment of Jerry W. Hussong, MD, as chief medical officer (CMO) and director of laboratories, effective, July 1, 2013. Hussong will be taking over the responsibility from Sherrie Perkins, MD, PhD. Perkins will transition into senior vice president, research and development; co-executive director, ARUP Institute for Clinical and Experimental Pathology; and division head of clinical pathology in the Department of Pathology at the University of Utah School of Medicine.
Predictive Biosciences Announces Partnership with ARUP Laboratories
Apr 2 13
Predictive Biosciences, Inc. announced a partnership with ARUP Laboratories, Inc. to offer the company's molecular diagnostic bladder cancer tests to ARUP's national network of clients. Through a non-exclusive agreement, ARUP will offer Predictive's CertNDx(TM) Bladder Cancer Assays in its comprehensive test menu to hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP's clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory. The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence post treatment. The test's unique approach stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.
ARUP Laboratories, Inc. Announces Availability of Natera's Non-Invasive Prenatal Test, Panorama(TM)
Mar 18 13
ARUP Laboratories, Inc. announced that Natera's non-invasive prenatal screening test, Panorama(TM), is available to ARUP clients nationwide. The test is available for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turner's syndrome). ARUP is a national reference laboratory that provides tests to an extensive network of U.S.-based hospitals. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as many other hospital networks and groups. Hospital laboratories provide patients with key tests that improve patient care, and are expected to play an increasingly important role in patient treatment as the use of molecular diagnostics grows. Hospital labs can order Panorama via ARUP's test code #2007537. In clinical validation studies, Panorama demonstrated a sensitivity of greater than 99% when detecting common chromosomal abnormalities such as trisomy 21, trisomy 18 and trisomy 13; and 92% when detecting monosomy X. In addition, the Panorama test has had no false positives for all the syndromes tested in three clinical trials. The test uses fetal cell-free DNA found in maternal blood and works as early as nine weeks gestation.
Similar Private Companies By Industry
Recent Private Companies Transactions